All In Biotech

Drug Trial Radar · NCT07124000

DESTINY-PANTUMOUR04

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 18, 2025

Primary completion

Mar 30, 2028

Study completion Mar 30, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Conditions

  • Adenocarcinoma (NOS)
  • Anal Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gall Bladder Cancer
  • Gastrointestinal Stromal Tumour
  • Head and Neck Cancer
  • Liver Cancer
  • Melanoma
  • Mouth Cancer
  • Nasopharangeal Cancer
  • Neuroendocrine, Gastrointestinal Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Salivary Gland Cancer
  • Sarcoma
  • Small Cell Lung Cancer
  • Testicular Cancer
  • Throat Cancer
  • Thyroid Cancer
  • Urethral Cancer
  • Vaginal Cancer
  • Vulvar Cancer

Interventions

  • Trastuzumab deruxtecanDrug

    Trastuzumab deruxtecan monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Real world response rate (rwRR)Time frame: Through study completion, up to 2.5 years after enrolment
  2. Real world duration of response (rwDoR)Time frame: Through study completion, up to 2.5 years after enrolment

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Bullhead City, Arizona · Recruiting

  • Research Site

    Casa Grande, Arizona · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    Boulder, Colorado · Recruiting

  • Research Site

    Coral Springs, Florida · Recruiting

  • Research Site

    St. Petersburg, Florida · Recruiting

  • Research Site

    West Palm Beach, Florida · Recruiting

  • Research Site

    Decatur, Illinois · Recruiting

  • Research Site

    Topeka, Kansas · Recruiting

  • Research Site

    Farmington, New Mexico · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Wilson, North Carolina · Recruiting

  • Research Site

    Canton, Ohio · Recruiting

  • Research Site

    Maumee, Ohio · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.